Krishna Komanduri: CMV reactivation after CAR-T therapy for lymphoma

Recently, an article by Rick Lin et al. titled “Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy” was published in Blood Advances.

Authors: Rick Y. Lin, Anthony D. Anderson, Yoichiro Natori, Mohammed Raja, Michele I. Morris, Antonio Jimenez Jimenez, Amer Beitinjaneh, Trent Wang, Mark Goodman, Lazaros Lekakis, Jay Spiegel, Noa G. Holtzman, Denise Pereira, Cara Benjamin, Akina Natori, Krishna V. Komanduri, Jose F. Camargo.

Krishna Komanduri, Physician in Chief at UCSF Helen Diller Family Comprehensive Cancer Center, shared a post on X:

“Very proud of this paper on CMV reactivation after CAR-T therapy for lymphoma, led by outstanding internal medicine resident Rick Lin and Jose Camargo.

Lots of lessons here about risks of immunotherapy.”

Blood Advances shared a post on X:

“Immunosuppression, particularly corticosteroids, for management of CAR T-cell toxicities is a major risk factor for CMV reactivation.”